Evidence map›Paper›PMID 31496650›Full record

SynthesisDrug design, development and therapy2019

Association between the c.415C > T, c.52G > A, and 36_37insGGAGTC polymorphisms of

Ruili Wang, Baogang Liu, Jiapeng Li, Jiamin Xu, Xiaoling Wang, Zhigang Zhao, Libo Zhao

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in Drug design, development and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Association ofHaematologica · 2024
    Pooled it
  2. Article
  3. The influence ofHGG advances · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ruili WangClinical Research Center, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, People's Republic of China.
Baogang LiuDepartment of Clinical Pharmacy, School of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
Jiapeng LiClinical Research Center, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, People's Republic of China.
Jiamin XuClinical Research Center, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, People's Republic of China.
Xiaoling WangClinical Research Center, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, People's Republic of China.
Zhigang ZhaoDepartment of Clinical Pharmacy, School of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
Libo ZhaoClinical Research Center, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, People's Republic of China.
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAs a common immunosuppressive and anticancer drug, thiopurine has achieved remarkable clinical success. However, higher inter-individual dose variability and unpredictable toxicity still challenge its use in clinical practices. Some studies indicate that

methodsThree databases were electronically searched: PubMed, Embase, and Web of Science. Only case-control studies and cohort studies were eligible. The overall pooled ORs and corresponding 95% CIs were used to represent the results.

findingsWe included 16 studies that focus on IMPLICATIONS:

Indexed as

MercaptopurineAlopeciaHumansLeukopeniaNudix HydrolasesPolymorphism, Single NucleotidePyrophosphatasesSeverity of Illness IndexMercaptopurineNudix HydrolasesNUDT15 protein, humanPyrophosphatasesintoleranceleukopeniameta-analysisNUDT 15polymorphismthiopurine

Identifiers

PMID31496650
PMCPMC6689127
OpenAlexW2964963606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.